Will Novo Nordisk stock hold $37.46 support as sellers control momentum?

Traders Union
All News
Stocks
Novo Nordisk falls 1.06% to $37.91

Highlights

Novo Nordisk reported real-world data showing reduced cardiovascular risk when escalating semaglutide dose versus switching to tirzepatide.
Novo Nordisk secured global rights to HRS-1596 outside greater China in a deal valued up to $2.6 billion.
Shares of Novo Nordisk closed at $37.91 with sustained bearish momentum and are expected to trade between $37.46 to $38.36 in the near term.

Pipeline expansion and positive trial data met with selling pressure

Novo Nordisk published new real-world evidence highlighting that increasing the dose of semaglutide led to a reduction in major adverse cardiovascular events compared to switching to Eli Lilly's tirzepatide, according to Benzinga. The company also secured global rights to HRS-1596 outside of greater China in a deal valued up to $2.6 billion, which expands its pipeline and international reach, as reported by Benzinga. Additionally, Novo Nordisk presented analysis at the European diabetes meeting in Milan showing adults with type 2 diabetes experienced a 6% lower relative risk of adverse outcomes when increasing their Ozempic dosage versus switching to Mounjaro, based on a Novo-funded study noted by Medicaldaily. These developments underscore Novo Nordisk's active product and clinical strategy, though price action has remained under broader selling pressure.

Multiple sell signals as NVO tests oversold technical boundaries

On the hourly chart, NVO is positioned below the MA-20 at $38.36 and MA-50 at $38.56, while on the daily chart it remains below the MA-200 at $45.78. The Ichimoku Kijun at $38.39 stands as immediate resistance. MACD and ADX both align with sell momentum, while the RSI registers at 32.17 (Sell), and both Stoch RSI and CCI are in oversold territory. Bull/Bear Power further indicates intraday selling advantage, with the Awesome Oscillator remaining neutral and not confirming the prevailing downside.

Range-bound trading expected as breakout risk remains subdued

In the coming days, NVO is likely to trade within the $37.46–$38.36 range, as current momentum suggests continued containment within this band. The probability of an upward rebound remains low unless a breakout above the $38.39 resistance occurs, while downside risk is notably higher if support at $37.46 is breached. Under typical volatility, the baseline expectation is for price to remain range-bound, with any move through these technical levels potentially establishing a fresh directional bias.

Viktoras Karapetjanc, Traders Union expert, sees Novo Nordisk maintaining strong fundamentals and strategic momentum, despite the current price dip. He believes new clinical data and pipeline expansion reinforce positive long-term sentiment, although near-term technicals remain under pressure. The analyst maintains a constructive outlook and expects renewed interest if resistance above $38.39 is reclaimed. "Underlying demand drivers remain intact, so I view this consolidation as a healthy pause before further strength resumes."

Earlier, analysts noted that Novo Nordisk was contending with persistent technical weakness despite notable advances in its pipeline and clinical portfolio. The current article strengthens this view, as recent strategic developments have yet to shift momentum, making the $38.39 resistance level a critical threshold to monitor for signs of trend reversal in the near term.

Source of Data: NVO Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.